Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2022—Elga LabWater has designed a range of clinical water purification systems under the product name Medica. The product line comprises six water purification systems to accommodate a range of clinical analyzers.
March 2022—Beckman Coulter Life Sciences has signed an agreement with Illumina to develop applications on the Biomek NGeniuS Next Generation Library Preparation System, which is scheduled to launch during the second quarter of this year. The applications will be available to Biomek NGeniuS system users via a first-of-its-kind electronic application library, the company says.
March 2022—Asuragen has launched a kit to detect pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The AmplideX PCR/CE CFTR Kit, for research use only, is designed to detect about 93 percent of CFTR pathogenic variants observed in the U.S. population.
February 2022—BD announced it has received 510(k) clearance from the FDA for the BD Kiestra IdentifA system, which is designed to automate the preparation of microbiology bacterial identification testing. The company says that by automating what are typically cumbersome manual steps, the BD Kiestra IdentifA may reduce the potential for human error when preparing samples for bacterial identification and produce more accurate diagnoses for patients.
February 2022—Bio-Rad Laboratories launched the Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays, for research use only. The assays allow scientists to measure neutralizing antibodies against wild-type and significant variants of the SARS-CoV-2 virus. The Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody 11-Plex Panel is a ready-to-use 96-well kit containing premixed magnetic capture beads, a detection ACE2 receptor, a standard and positive control, and buffers that measure levels of neutralizing antibodies and percentage inhibition of the ACE2 receptor binding the viral antigens coupled on the beads.
February 2022—Qiagen and Denovo Biopharma will collaborate to develop a blood-based companion diagnostic test to identify patients expressing Denovo Genomic Marker 1 (DGM1) who are likely to respond to Denovo’s investigational cancer drug DB102 for treatment of diffuse large B-cell lymphoma. DB102 (enzastaurin) is an investigational small molecule inhibitor of PKC-beta, which, if present, has been linked to DLBCL cases.
February 2022—Verichem Laboratories offers an array of liquid-stable, ready-to-use multilevel reference materials for total cholesterol, high-density lipoprotein, and low-density lipoprotein testing. The Matrix Plus Total Cholesterol Reference Kit, the Matrix Plus Total Cholesterol Reference Level F, and the HDL Cholesterol Verifier Kit are intended for calibration verification and are compatible with a variety of wet chemistry clinical analyzers.
February 2022—Biodesix announced the launch of its GeneStrat NGS genomic test, a blood-based tumor profiling test. The 52-gene panel includes guideline-recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others.
February 2022—EliTechGroup MDx announced its research use only SARS-CoV-2 Extended test kit reliably differentiates the SARS-CoV-2 omicron (B.1.1.529) variant from other variants of concern. The in silico analysis was confirmed by testing patient samples positive for different SARS-CoV-2 variants including omicron. The SARS-CoV-2 Extended RUO reagents differentiate the alpha, beta, gamma, delta, and omicron variants in a single multiplex PCR and test for the presence of specific mutations in the regions of the S gene corresponding to positions 452, 484, and 501 of the spike protein. The combination of the melting curve analysis and the optical channel information allows for unambiguous differentiation of the five SARS-CoV-2 variants. The results can be interpreted and released when the reagents are used on the sample-to-result Elite InGenius system.
February 2022—Roche announced that the FDA has granted emergency use authorization for its COVID-19 At-Home Test. The test uses an anterior nasal swab sample that can be self-collected and self-tested by people ages 14 years and older and by an adult for children ages two to 13 years old. Results are available in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including omicron.
